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Aim: Alpha-1-antitrypsin (A1AT) is the main inhibitor of neutrophil elastase, and severe alpha-1-antitrypsin
deficiency (A1ATD) is a genetic risk factor for early-onset emphysema. Despite the relatively high prevalence of
A1ATD, this condition is frequently underdiagnosed. Our aim was to determine the distribution of the A1ATD
phenotypes/alleles in patients with lung diseases as well as in the Serbian population. Methods: The study
included the adults with chronic obstructive pulmonary disease (COPD) (n = 348), asthma (n = 71), and bron-
chiectasis (n = 35); the control was 1435 healthy blood donors. The A1ATD variants were identified by isoelectric
focusing or polymerase chain reaction-mediated site-directed mutagenesis. Results: PiMZ heterozygotes, PiZZ
homozygotes, and Z allele carriers are associated with significantly higher risk of developing COPD than healthy
individuals (odds ratios 3.43, 42.42, and 5.49 respectively). The calculated prevalence of PiZZ, PiMZ, and PiSZ
was higher in patients with COPD (1:202, 1:8, and 1:1243) than in the Serbian population (1:5519, 1:38, and
1:5519). Conclusion: The high prevalence of A1ATD phenotypes/allele in our population has confirmed the
necessity of screening for A1ATD in patients with COPD. On the other hand, on the basis of the estimated
number of those with A1ATD among the COPD patients, it is possible to assess the diagnostic efficiency of
A1ATD in the Serbian population.
Introduction
Alpha-1-antitrypsin (A1AT) is an acute-phase glyco-protein that is mainly synthesized in hepatocytes and
subsequently secreted into the plasma. Besides the liver, small
quantities of A1AT are produced by alveolar macrophages,
circulating monocytes, and intestinal-, renal-, and lung-
derived epithelial cells (Cichy et al., 1997). Extrahepatic syn-
thesis of A1AT is important in preventing tissue damage in
the site of inflammation or injury. The target proteases of
A1AT originate from azurophilic granules of polymorpho-
nuclear neutrophils. The main physiological role of A1AT is
protection of the lower respiratory tract by inhibition of
neutrophil elastase (NE), which is released from triggered
neutrophils. Moreover, A1AT has anti-inflammatory proper-
ties ( Janciauskiene et al., 2007; Pott et al., 2009; Bergin et al.,
2010), and inhibits the lung endothelial cell apoptosis, which
is crucial for the maintaining pulmonary homeostasis
(Petrache et al., 2006).
A1AT is encoded by the SERPINA1 gene (serpin peptidase
inhibitor, clade A), located in the proteinase inhibitor (Pi)
locus on the long arm of chromosome 14q32.1, and shows a
codominant pattern of inheritance. SERPINA1 is highly
polymorphic, and more than 125 single-nucleotide polymor-
phisms (SNPs) have been reported in public SNP databases
(Entrez SNP). Protein variants of A1AT are classified by the Pi
(Protease inhibitor) system. Most common PiM variants have
a normal serum level and functional activity to inhibit NE.
The main characteristic of hereditary alpha-1-antitrypsin
deficiency (A1ATD) is a low level of circulating A1AT. The
post-translational modification of the A1ATD variants is al-
tered. Misfolded protein has a high tendency to form oligo-
mers and larger polymers that are retained in the hepatocytes,
and consequently leads to the reduction of circulating A1AT
(Carrell and Lomas, 1997). Because the integrity of lung al-
veoli depends on the proper levels of circulating A1AT, severe
A1ATD was identified as a genetic risk factor for early-onset
emphysema. Thus, the imbalance of protease–antiprotease
leads to A1ATD-related emphysema due to the excessive
activity of NE, which degrades the insoluble elastin and the
other components of the extracellular matrix in the lower
respiratory tract.
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Several mutations associated with A1ATD have been
identified, and the most common are the Z and S alleles. The
plasma levels of A1AT in PiZZ homozygotes are severely
reduced (10–15% of normal), whereas in the PiSS, PiMS,
PiMZ, and PiSZ heterozygotes, the reduction ismild (35–70%).
The aim of this study was to estimate the prevalence of
A1ATD in the patients with lung disease. To our knowledge,
these data for our population do not exist. Two A1ATD
epidemiological studies (De Serres, 2002; Blanco et al., 2006)
have included data for the Serbian population. Our intention
was to update the data and estimated number of A1ATD
individuals in the Serbian population.
Methods
Study subjects
The study included adult patients with lung disease ad-
mitted to the Clinic for Pulmonary Diseases Clinical Centre of
Serbia, Belgrade, Serbia, and the ZvezdaraUniversityMedical
Center. The study included 348 patients with chronic ob-
structive pulmonary disease (COPD), 71 with asthma, and 35
with bronchiectasis. The control group included 1435 healthy
blood donors. The diagnosis of COPD was established based
on medical history, physical examination, pulmonary func-
tion tests, blood gas analyses, and chest radiography, ac-
cording to the Global Initiative for Chronic Obstructive Lung
Disease. Patients with bronchiectasis had symptoms, includ-
ing regular sputum production, chronic cough, and a history
of recurrent lower respiratory tract infections. The diagnosis
of bronchiectasis was established by chest high-resolution
computed tomography. Pulmonary function tests (forced
expiratory volume in 1 s [FEV1] and forced vital capacity)
were performed. The diagnosis of asthma was based on the
history of attacks of wheezing associated with shortness of
breath and spirometric evidence of a bronchodilator response.
The protocol has been approved by the local research ethics
committees, and informed consent was obtained from all
participants of the study.
Methods
Blood samples were taken from all patients. Sera were
separated by centrifugation and stored at - 80C until ana-
lyzed. For detection of A1ATD variants, isoelectric focusing or
polymerase chain reaction (PCR)-mediated site-directed
mutagenesis (PSM) methods were employed, depending on
the method available in the laboratory at a particular time.
Isoelectric focusing method (pH range 4.2–4.9; Pharmacia
LKB Biotechnology) (Kishimoto et al., 1990) was performed
with an LKB 2117 Multiphor system. Serum samples were
pretreated by dithioerythritol, and 0.2-mm-thin polyacryl-
amide gels were casted by using the Pharmacia LKB Ul-
tromould Gel Casting Unit (Pharmacia).
Genomic DNA was extracted from peripheral blood using
a GFXTM Genomic Blood DNA Purification Kit (Amersham
Biosciences). The presence of the most common mutated
A1AT alleles, Z and S, was detected by the PSMmethod, as it
was previously described (Lucotte and Sesbou¨e´, 1999). In
summary, fragments containing Z and S mutations were
coamplified; PCR products were digested with TaqI (New
England BioLabs), separated on a 4% agarose gel, and visu-
alized by ethidium bromide staining. Genotypes were scored
without knowledge of the sample phenotypes by two inde-
pendent observers.
Statistical analysis
The differences in the frequencies of A1AT phenotypes and
alleles between patients and controls were analyzed using the
v2 test (2 · 2 contingency table). The Fisher exact test was used
when n < 5. p-Values of < 0.05 were considered as significant.
For statistical analysis, Statistica 7.0 software was used.
Results
Frequencies of A1ATD phenotypes/alleles in patients with
lung disease and controls are presented in Table 1. Sig-
nificantly higher frequencies of PiMZ, PiZZ, and Z alleles
were obtained only in COPD patients. Our data showed that
PiMZ heterozygotes have 3.4-times higher risk of developing
COPD, while a severe A1ATD in PiZZ homozygotes is asso-
ciated with very high risk for COPD, 42-times higher than
individuals without this phenotype. The carriers of the Z
allele have 5.5-times higher risk of developing COPD than the
carriers of other alleles.
Estimated prevalence and the number of A1ATD patients
with COPD, and A1ATD individuals in the Serbian popula-
tion without COPD are given in Table 2. The estimation was
made based on the prevalence of COPD in the Serbian
Table 1. Alpha-1-Antitrypsin Deficiency Phenotypes and Alleles in Patients
with Lung Diseases and in Control Group (Frequencies/Number)
COPD
(n= 348)
Asthma
(n = 71)
Bronchiectasis
(n = 35)
Control
(n = 1435)
Odds ratio
(95% CI)
Phenotypes
MM 0.8764/305a 0.9577/68 0.9715/34 0.9603/1378 0.31 (0.20–0.47)
MZ 0.0833/29a 0.0281/2 0.0286/1 0.0258/37 3.43 (2.08–5.67)
ZZ 0.0287/10a 0 0 0.0007/1 42.42 (4.41–332.55)
MS 0.0115/4 0.0140/1 0 0.0132/19 —
Alleles
M 0.9239/643a 0.9789/139 0.9857/69 0.9798/2812 0.25 (0.17–0.37)
Z 0.0704/49a 0.0141/2 0.0143/1 0.0136/39 5.49 (3.58–8.44)
S 0.0057/4 0.0070/1 0 0.0066/19 —
aSignificant difference compared to control ( p = 0).
COPD, chronic obstructive pulmonary disease; CI, confidence interval.
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population of 6% (Franchi, 2009), and the size of Serbian
population (Official Website of the Serbia Government,
www.srbija.gov.rs/pages/article.php?id = 6). According to
these data, the estimate is that of 7,120,666 Serbian citizens,
427,240 individuals will be affected with COPD.
The frequency of the S allele in our population was low
(< 1%), and the association with COPD was not observed.
Nevertheless, the S allele and S allele carriers are presented in
Table 2, due to the association between S allele carriers and
COPD (Dahl et al., 2005). In this meta-analysis, the risk of
COPD is approximately tripled in PiSZ, and significantly in-
creased in PiMS carriers. Although the risk for COPD in the
PiMS subgroup adjusted for smoking or COPD based on
spirometry were not increased, the authors could not com-
pletely exclude the possibility of PiMS genotype importance
in the pathogenesis of COPD.
The prevalence of A1ATD phenotypes in Serbian and
European patients with COPD and corresponding popula-
tions is given in Table 3. This table presents the current data
for the Serbian population, aswell as the estimated prevalence
of the PiS and PiZ gene calculated by Blanco et al. (2006) based
on data from 21 European countries. The data obtained in a
recent study conducted in Ireland (Carroll et al., 2011) are also
included.
Discussion
The risk of COPD development caused by hereditary
A1ATD is inversely correlated with level of serumA1AT. The
American Thoracic Society/European Respiratory Society
Statement (2003) recommended quantitative testing of A1AT
in all patients with COPD, in those with asthma characterized
by incompletely reversible airflow obstruction and in patients
with bronchiectasis without evident etiology. Severe A1ATD
phenotypes, PiZZ, PiSZ, and PiNull, or carriers of some other
rare variants are significantly associated with panlobular
emphysema. Typically, clinical manifestations of A1ATD-
related emphysema are dilatation or destruction of all lower
lobules. The PiMZ heterozygotes have mild reduction of the
circulating A1AT. Although, the data regarding the risk of
COPD in PiMZ individuals are inconsistent, a significant
number of representative studies have shown the association
between PiMZ and COPD. These studies have shown the
Table 2. Estimated Prevalence and Number of Alpha-1-Antitrypsin Deficiency
in Patients with Chronic Obstructive Pulmonary Disease
and in Serbian Population Without Chronic Obstructive Pulmonary Disease
Observed
number
Observed
frequency
Expected
number
Expected
frequency
Estimated
prevalencea
Estimated
numberb
COPD (n = 348)
Phenotypes
MM 305 0.8764 297.05 0.8535 / /
MZ 29 0.0833 45.27 0.1300 1:8 55,578
ZZ 10 0.0287 1.72 0.0049 1:202 2112
MS 4 0.0115 3.66 0.0105 1:95 4493
SZ 0 0 0.28 0.0008 1:1243 344
SS 0 0 0.01 0.0001 1:34,800 12
Alleles
M 643 0.9239
Z 49 0.0704
S 4 0.0057
Control (n = 1435)
Phenotypes
MM 1378 0.9603 1377.6 0.9600 / /
MZ 37 0.0258 37.97 0.0264 1:38 177,108
ZZ 1 0.0007 0.26 0.0002 1:5519 1212
MS 19 0.0132 18.37 0.0128 1:78 85,685
SZ 0 0 0.26 0.0002 1:5519 1212
SS 0 0 0.06 0.0000 1:23,917 280
Alleles
M 2812 0.9798
Z 39 0.0136
S 19 0.0066
aPrevalence of COPD in Serbia is 6%; for the calculation, the estimated number of 427,240 patients with COPD was used.
bPopulation of Serbia consists of 7,120,666 inhabitants; for the calculation, the estimated number of 6,693,426 individuals without COPD
was used.
Table 3. Prevalence of Alpha-1-Antitrypsin
Deficiency Phenotypes in Serbia and in Europe
COPD
Populations
Phenotypes
Serbia-this
study
Serbia-this
study Serbiaa Europea Irelandb
MZ 1:8 1:38 1:40 1:36 1:25
ZZ 1:202 1:5519 1:6165 1:4727 1:2104
MS 1:95 1:78 1:77 1:16 1:10
SZ 1:1243 1:5519 1:5945 1:1051 1:424
SS 1:34,800 1:23,917 1:22,931 1:934 1:341
aBlanco et al. (2006).
bCarroll et al. (2011).
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decrease in elasticity and deterioration of lung function pa-
rameters (Tarja´n et al., 1994), greater rate of decrease in FEV1
(Dahl et al., 2002), higher susceptibility to the development of
airflow obstruction (Sørheim et al., 2010), and increased odds
of COPD in PiMZ individuals (Hersh et al., 2004). On the other
hand, the mild deficiency in the PiMZ heterozygote is suffi-
cient for antielastase defense of the lung and contributes to a
lower-penetrance PiMZ phenotype than PiZZ.
Current results in Serbian adults confirmed that the severe
A1ATD (PiZZ), mild A1ATD (PiMZ), and Z alleles represent
high risk factors for COPD (odds ratios [ORs]: 42.42, 3.43, and
5.49, respectively). Our data correspond to the data from the
study by Koyama and Geddes (1998). In that study, compiled
data from 10 case–control studies from different populations
were presented, and ORs for PiZZ and for PiMZ were 38.85
and 2.48, respectively. Furthermore, in the current study, 2.9%
of COPD patients were PiZZ, which corresponds with the
report of the World Health Organization (1997) that 2–3% of
all emphysema patients are PiZZ. Therefore, WHO re-
commended screening for A1ATD in patients with COPD and
emphysema. In addition, we observed that among COPD
patients, 8.3% were PiMZ, which is similar to the data ob-
tained in Danish patients with clinically established COPD
(6.3%) (Dahl et al., 2001). However, screening of an unselected
population with COPD, asthma, and bronchiectasis in Ger-
many (Wencker et al., 2002) detected that frequencies of PiMS
and PiMZ were similar to the healthy population, and the
PiZZ homozygotes in patients with asthma or COPD were
very rare (< 0.1%). The most common reasons that lead to the
inconsistent results in COPD-A1ATD association studies are
differences in population genetics, in stratification of COPD
patients and in COPD phenotype definition. Regarding PiMZ
heterozygosity, further reason for the discrepancies between
studies is that the phenotype is often unrecognized due to the
mild symptoms of COPD.
Although emphysema represents a predominant clinical
manifestation of COPD in A1ATD, investigation of other
airway diseases associated with the A1ATD is in progress.
Published data regarding the association between bronchi-
ectasis and A1ATD are controversial (Cuvelier et al., 2000;
Parr et al., 2007). Cuvelier et al. (2000) concluded that bron-
chiectasis may be a consequence of emphysema in PiZZ
patients rather than a primary effect. The influence of irre-
versible airflow obstruction in patients with severe A1ATD on
the prevalence of asthma is also unclear. Recent review (Eden,
2010) was shown that the asthma signs and symptoms were
common in A1ATD individuals with or without COPD, be-
cause A1ATD itself predisposes for hyper-responsiveness of
the airway. We did not find association between asthma and
bronchiectasis with A1ATD phenotypes or alleles. In rela-
tively small number of patients with asthma and bronchiec-
tasis, the deficient Z allele was about five-times less frequent
than in COPD patients, and almost equal with the control.
Therefore, we can assume that A1ATD is not dominant in the
pathogenesis of these lung diseases.
Although epidemiological studies have revealed a large
number of individuals with A1ATD worldwide (De Serres,
2002), this condition is often undiagnosed, and exact preva-
lence of A1ATD in most population remains unknown. Also,
study about psychosocial and ethics issues faced by adults at
the risk for A1ATD has revealed that the education and di-
agnosis of A1ATD need to be improved (Klitzman, 2009).
Globally, A1ATD affects all major racial subgroups. There
are at least 116 million carriers (PiMZ and PiMS) and 3.4
million deficiency allele’s combinations (PiSS, PiSZ, and
PiZZ) worldwide (De Serres, 2002). Most of A1ATD cases are
misdiagnosed as COPD or nonresponsive asthma. As a result,
long delays between the presentation of first symptoms and
the correct diagnosis are common (Stoller et al., 2005). The
main causes of this situation are the presence of similar re-
spiratory symptoms to those seen in asthma or COPD, and
sporadic occurrence of symptoms such as shortness of breath,
cough, excess sputum production, reduced ability to exercise,
and wheezing. Therefore, it is important to estimate the
prevalence of A1ATD to predict the number of potential users
of medical services and also to evaluate the efficacy of A1ATD
diagnostics in a particular population. All this could improve
the early detection of A1ATD and early prevention of symp-
toms. In the current study, we attempted to estimate the
prevalence of A1ATD in 348 of COPD patients, as well in 1435
control subjects. Assuming the Hardy–Weinberg equilibrium
in a population of Serbia, calculated prevalence of PiZZ,
PiMZ, PiMS, and PiSZ were 1:5519, 1:38, 1:78, and 1:5519,
respectively. Prevalence for the Z allele carriers in our popu-
lation corresponds to the prevalence in the total European
population and previously analyzed data of the Serbian
population published in the study by Blanco et al. (2006)
(Table 3).
The prevalence of the S allele varies greatly in different
European populations. Current study confirmed lower
prevalence of the S allele in our population (0.0066) in com-
parison to the total European population (0.0330). The prev-
alence of the S allele in our population is most in correlation
with the neighboring Romanian population (0.0055) (De
Serres et al., 2007). The recent data (Carroll et al., 2011) dem-
onstrated that A1ATD in Ireland is among the highest in the
world. In the population of Ireland, a nearly two-times higher
frequency of homozygotes and 10-times higher frequency of
heterozygotes for the PiZ allele, in comparison to our popu-
lation, were reported.
We obtained significantly higher prevalence of PiZZ, PiMZ,
and PiSZ in COPD patients than in non-COPD subjects.
Moreover, one of the eight COPD patients in Serbia has PiMZ,
and 1 of 202 has the PiZZ genotype. If we take into account the
prevalence of COPD in our population, as well the expected
number of A1ATD, we estimate that 55,578 PiMZ, 2112 PiZZ,
4493 PiMS, and 344 PiSZ individuals would clinically mani-
fested COPD. These data are an approximation. It must be
taken into consideration that only 0.35% of severe A1ATD
(PiZZ and PiSZ) are recognized (Luisetti and Seersholm, 2004),
whereas data for the mild A1ATD (PiMZ, PiMS) do not exist.
Based on the estimates of the total number of the Z
homozygotes and heterozygotes in our population, we
calculated that the 24% of total number of PiMZ and even 63%
of PiZZ should show clinical symptoms of COPD. The case-
detection program in Spain (De la Roza et al., 2005) identified
0.37% PiZZ individuals in a population of COPD patients.
Taking that estimated prevalence of COPD in Spain is 9%,
they speculated that between 35% and 60% of all PiZZ
develop COPD. Although the prevalence of COPD in our
population is lower (6%) than in the Spanish (9%), prediction
of PiZZ individuals that could develop COPD is comparable.
In conclusion, current study reveals that the prevalence of
A1ATD in the Serbian population is comparable to data for
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total European population. The other finding is a high prev-
alence of PiZZ and PiMZ among COPD patients, which
confirms the need for early screening for A1ATD in patients
with mild and severe symptoms of COPD. Current data allow
the comparison of the estimated number of A1ATD patients
with clinical manifestation of COPD and those who are
actually diagnosed by physician, to assess the efficiency of
detection of A1ATD. Since there is no national register of
A1ATD patients in Serbia, our data could represent a good
starting point to justify the need for such register. An early
detection of COPD caused by A1ATD is of great importance,
as in the modification of life style, and the application of
therapeutic approaches could modulate the occurrence of
severe symptoms of COPD or alleviate them.
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